| Nov 14 |
Vaccine makers close lower amid reports RFK Jr may head HHS (update)
|
| Nov 14 |
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
|
| Nov 14 |
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
|
| Nov 14 |
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
|
| Nov 14 |
Merck to buy rights to Chinese cancer drug for up to $3.3B
|
| Nov 14 |
Merck to Participate in the Jefferies London Healthcare Conference
|
| Nov 14 |
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
|
| Nov 14 |
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
|
| Nov 13 |
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)
|
| Nov 13 |
Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial
|
